Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy

Aim. - This study evaluated the effects of a glucagon-like peptide-1 receptor agonist on gastrointestinal (GI) tract motility and residue rates by examining GI transit time and lumen using capsule endoscopy. Material and methods. - GI motility and lumen were assessed by capsule endoscopy before and after liraglutide administration in 14 patients with type 2 diabetes mellitus (T2DM). Results. - Gastric transit time in the group with diabetic neuropathy (DN) was 1:12:36 +/- 1:04:30 h before liraglutide administration and 0:48:40 +/- 0:32:52 h after administration (nonsignificant difference, P = 0.19). Gastric transit time in the non-DN group was 1:01:30 +/- 0:52:59 h before administration and 2:33:29 +/- 1:37:24 h after administration (significant increase, P = 0.03). Duodenal and small intestine transit time in the DN group was 4:10:34 +/- 0:25:54 h before and 6:38:42 +/- 3:52:42 h after administration (not significant, P = 0.09) and, in the non-DN group, 3:51:03 +/- 0:53:47 h before and 6:45:31 +/- 2:41:36 h after administration (significant increase, P = 0.03). The GI residue rate in the DN group was 32.1 24% before administration and 90.0 +/- 9.1% after administration (significant increase, P < 0.001), and increased in all patients; in the non-DN group, it was 32.1 +/- 35.3% before and 78.3 +/- 23.9% after administration (significant increase, P < 0.001), and also increased in all patients. Conclusion. - Liraglutide causes delayed gastric emptying and inhibits duodenal and small intestine motility. However, these GI movement-inhibiting effects may be decreased or absent in patients with DN-associated dysautonomia. (C) 2017 The Author(s). Published by Elsevier Masson SAS.